Alireza Hasheminasab
Lead Computational and AI/ML Research Scientist
Dr Seyed Alireza Hasheminasab is a computer scientist currently working as a Postdoctoral Research Associate at the Oxford Translational Myeloma Centre (OTMC). His research focuses on the development and application of advanced AI and machine learning methods for the analysis of complex, multi-modal healthcare and omics datasets. Since joining OTMC in February 2024, he has led a range of computational analyses to support translational research and precision medicine initiatives.
He brings substantial experience working with large-scale datasets, including CPRD, the NHS England Secure Data Environment (SDE), and UK Biobank, alongside institutionally curated datasets. Prior to this role, Alireza was a Postdoctoral Data Scientist in the Pharmaco- and Device Epidemiology Group at the Centre for Statistics in Medicine (CSM), where he contributed to the fine-tuning and evaluation of healthcare-specific large language models and developed predictive models in clinical contexts.
In addition to his academic work, Alireza has over 12 years of experience in industry, where he applied computer science to solve a wide range of interdisciplinary problems across sectors.
Recent publications
I-based analysis reveals novel blood protein biomarkers for predicting cardiac amyloidosis approximately a decade early: a UK biobank study
Conference paper
Hasheminasab A. et al, (2025), Blood, 146
nti-Adhesion Properties of KTX-1001, a Selective NSD2/MMSET Inhibitor, Enhance Carfilzomib Sensitivity in Multiple Myeloma
Journal article
Nandana D. et al, (2025), Clinical Lymphoma Myeloma and Leukemia, 25, S213 - S214
Ensuring Equity in AI: Addressing Data-Driven Biases in Health-specific Large Language Models for Global Use
Other
Khalid S. et al, (2025)
High Expression of NSD2 in Non t (4;14) Newly-Diagnosed Multiple Myeloma Patients May Mimic t (4;14) Biology
Conference paper
Samur M. et al, (2025), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 25
nti-Adhesion Properties of KTX-1001, a Selective NSD2/MMSET Inhibitor, Enhance Carfilzomib Sensitivity in Multiple Myeloma
Conference paper
Nandana D. et al, (2025), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 25